AR1001 (mirodenafil) is an erectile dysfunction drug being repurposed for Alzheimer’s because it shows potential neuroprotective effects. The drug failed to slow decline in its Phase 2 study. A larger Phase 3 trial, using the same approach is set to read out later this year to provide a more definitive answer.